DIRECTIONALLY ATTENUATED VACCINIA VIRUS VACCINE

The present invention relates to a recombinant vaccinia virus and the use thereof. Compared with vaccinia virus Tiantan strain, the recombinant vaccinia virus does not comprise at least one of TK gene, F4L gene and B2R gene. The recombinant vaccinia virus of the present invention has characteristics of low toxicity, capability of being completely replicated and higher immunogenicity. Thus, the recombinant vaccinia virus provided by the present invention has higher safety and enhanced immunogenicity. The recombinant vaccinia virus provided by the present invention has higher application values as a vaccine, can be used for preventing infection of viruses of family poxviridae, and can be used as a viral vector for constructing other infectious-disease vaccines, tumor vaccines and the like. La présente invention concerne un virus de la vaccine recombiné et son utilisation. Par comparaison avec la souche Tiantan du virus de la vaccine, le virus de la vaccine recombiné ne comprend pas au moins l'un parmi le gène T